Extracorporeal CO2 Removal Devices Market

The extracorporeal CO2 removal devices market is anticipated to expand from US$ 112.5 million in 2024 to US$ 184.36 million by 2031, with a projected CAGR of 6.4% from 2025 to 2031.

Market Insights and Analyst Perspective:The growth of the extracorporeal CO2 removal devices market is driven by the rising prevalence of chronic obstructive pulmonary diseases (COPD) and an increasing elderly population. However, stringent regulations concerning extracorporeal CO2 removal devices pose challenges to market growth.

Extracorporeal CO2 removal devices are recognized for their safety, effectiveness, and feasibility. Their application in ventilatory support is recommended in clinical scenarios where they can help manage exacerbations of COPD and acute respiratory distress syndrome. Numerous manufacturers are concentrating on creating technologically advanced and innovative extracorporeal CO2 removal devices to enhance their market presence. Additionally, a growing number of elderly patients susceptible to COPD are being connected to extracorporeal CO2 removal devices to boost their survival rates. Consequently, the rising incidence of pulmonary obstructive diseases is a significant factor contributing to the expansion of the extracorporeal CO2 removal devices market size. Conversely, the use of these devices carries risks such as infection, hypoxemia, or thrombosis due to restricted blood flow, which can lead to severe health issues and present a long-term challenge to market growth.

Growth Drivers:Rising Incidence of Chronic Obstructive Pulmonary Diseases Fuels Extracorporeal CO2 Removal Devices Market

The Burden of Disease Study in 2019 reported 212.3 million cases of COPD and 3.3 million COPD-related deaths worldwide. A significant contributor to respiratory diseases like COPD is the increasing air pollution. Furthermore, the Organization for Economic Co-operation and Development (OECD) predicts that global greenhouse gas emissions will rise by approximately 50% by 2050, with CO2 emissions increasing by 70%. It is also estimated that atmospheric concentrations of greenhouse gases could reach 685 parts per million (ppm) CO2 equivalent by 2050, potentially causing average temperatures to rise by 3 to 6°C above pre-industrial levels.

In January 2021, a study published in the journal PLoS ONE indicated that around 2.6 million individuals in France were affected by COPD, with projections suggesting this number will increase to 2.8 million by 2025. According to 2022 data from National Health Science, approximately 1.17 million people were diagnosed with COPD in England during 2020-21, accounting for 1.9% of the total population. The WHO identifies COPD as the third leading cause of death globally, resulting in about 3.2 million deaths in 2022. Additionally, the American Lung Association reports that over 11 million people in the US are diagnosed with COPD annually. Thus, the substantial burden of COPD within the population drives the demand for extracorporeal CO2 removal devices to enhance blood flow and facilitate efficient gas exchange, thereby propelling the growth of the extracorporeal CO2 removal devices market.

Strategic Insights

Report Segmentation and Scope:The "extracorporeal CO2 removal devices market analysis" has been conducted by examining the following segments: product, application, and end user.

Segmental Analysis:In terms of application, the extracorporeal CO2 removal devices market is divided into acute respiratory distress syndrome, chronic obstructive pulmonary disease, and others. The chronic obstructive pulmonary disease segment accounted for the largest market share in 2022. The acute respiratory distress syndrome segment is expected to exhibit the highest CAGR of 7.7% during the forecast period. Growing awareness of ARDS and its early detection has led to an increase in patient diagnoses and treatments, resulting in heightened demand for extracorporeal CO2 removal devices designed for ARDS management. Consequently, healthcare providers are increasingly confident in integrating extracorporeal CO2 removal devices into their ARDS treatment protocols.

Extracorporeal CO2 removal devices facilitate a reduction in respiratory rate and tidal volume, leading to an extended expiratory time that aligns better with the respiratory system's high expiratory time constant. The British Lung Association estimates that around 1.2 million individuals in the UK are living with diagnosed COPD. Therefore, the rising prevalence of COPD is expected to accelerate the global extracorporeal CO2 removal devices market.

By product, the extracorporeal CO2 removal devices market is categorized into extracorporeal CO2 devices and consumables. The extracorporeal CO2 devices segment held a larger market share in 2022, while the consumables segment is projected to achieve a higher CAGR of 7.6% during the forecast period. Due to technical simplifications, extracorporeal CO2 removal devices require fewer personnel and logistics, enhancing patient preference. This has allowed the extracorporeal CO2 removal devices segment to maintain its market position.

The process of extracorporeal CO2 removal necessitates a fresh set of consumables for each patient, resulting in a high demand for consumables in various COPD and ARDS-related procedures. Thus, the market for the consumables segment of extracorporeal CO2 removal devices is expected to continue its growth during the forecast period.

By end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment captured the largest share of the extracorporeal CO2 removal devices market in 2022 and is expected to register the highest CAGR of 7.4% during the forecast period. Hospitals, particularly those with specialized intensive care units (ICUs) and respiratory facilities, are equipped to care for the most critically ill patients. Moreover, hospitals typically have multidisciplinary teams of healthcare professionals, including pulmonologists, critical care physicians, respiratory therapists, and perfusionists, who collaborate to treat patients with complex respiratory needs. This expertise is crucial for the safe and effective use of ECCO2R devices.

Technological Advancements to Propel Extracorporeal CO2 Removal Devices Market

Smaller extracorporeal CO2 removal devices are less invasive and provide greater comfort for patients. They often require smaller vascular access, which reduces the risk of complications. As patients are not confined to large, immobile devices, they can enjoy increased mobility and comfort, enhancing the overall quality of treatment. Advances in membrane technology have significantly improved the effectiveness and efficiency of extracorporeal CO2 removal devices, allowing selective diffusion of CO2 while preserving essential blood components such as red blood cells and proteins. This selectivity reduces the risk of hemolysis and other blood-related complications.

With the growing need to maintain quality of life in the aging population due to their declining health conditions, extracorporeal CO2 removal devices are vital in providing less invasive and gentler respiratory support. Technological innovations in extracorporeal CO2 removal (ECCO2R) have led to the creation of more user-friendly and portable devices. As the benefits of ECCO2R become increasingly recognized, it is being integrated into treatment plans for older adults. Therefore, ongoing technological advancements are likely to introduce new trends in the extracorporeal CO2 removal devices market in the coming years.

Regional Analysis:The scope of the extracorporeal CO2 removal devices market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest share of the extracorporeal CO2 removal devices market. The growth in this region is attributed to enhanced healthcare infrastructure and a high adoption rate of extracorporeal CO2 removal devices, particularly during the COVID-19 pandemic in the US and Canada. The early adoption of new technologies and a large patient population for ARDS and COPD are expected to further accelerate market growth in the region. The rising incidence of chronic respiratory diseases and a preference for safe, rapid, minimally invasive ventilators are also anticipated to boost the growth of the extracorporeal CO2 removal devices market during the forecast period.

Europe is expected to hold the second-largest share of the global extracorporeal CO2 removal devices market, driven by increasing demand for healthcare devices and a rising prevalence of chronic diseases such as respiratory failure in the region. Additionally, favorable reimbursement policies, increased government investments in long-term healthcare, and enhanced healthcare research infrastructures are contributing to higher utilization rates of extracorporeal CO2 removal devices.

The extracorporeal CO2 removal devices market in the Asia Pacific region is projected to experience the fastest growth rate of 7.3% during the forecast period. This growth is fueled by a large patient population, heightened awareness of acute respiratory failure, and increased government healthcare spending in developing countries like India and Japan. Furthermore, multinational companies are looking to invest in developing countries such as China, thereby promoting market growth in the region.

Extracorporeal CO2 Removal Devices Market Report Scope

Industry Developments and Future Opportunities:The forecast for the extracorporeal CO2 removal devices market can assist stakeholders in planning their growth strategies. Below are some strategic developments by leading players in the market:

In October 2022, ALung Technologies assessed the safety and effectiveness of the hemolung respiratory assist system (RAS) for low-flow extracorporeal CO2 removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients needing respiratory support due to acute exacerbations of chronic obstructive pulmonary disease (COPD).

In March 2022, Respira Labs, a US-based respiratory health technology firm, launched Sylvee, an AI-powered wearable lung monitor that utilizes acoustic resonance to evaluate lung function and detect fluctuations in lung volume. This device can aid in the detection and treatment of chronic obstructive pulmonary disease, asthma, and COVID-19.

In May 2021, ALung Technologies, Inc. received FDA clearance for its next-generation Hemolung RAS extracorporeal CO2 removal system, designed to provide respiratory support to patients experiencing acute respiratory failure.

In May 2020, ALung Technologies, Inc. announced the commercial development of the next-generation artificial lung known as the hemolung RAS.

Competitive Landscape and Key Companies:Key companies profiled in the extracorporeal CO2 removal devices market report include Getinge, ALung Technologies, Inc., Estor, NovaLung GmbH, Hemodec, Baxter Healthcare, Eurosets, LivaNova, Medtronic, and Xenios AG. These companies are focused on developing new technologies, enhancing existing products, and expanding their geographic reach to meet the growing global consumer demand.